Page 11 - reflections_dyslipidaemia_newsletter5_2023

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #5 2023

A treatment algorithm for homozygous (bi-allelic) FH is presented, with specific LDL-C goals for children/ adolescents and for adults
with or without major ASCVD risk factors. Treatments include the cornerstone of statins and ezetimibe, along with PCSK9i, and the
novel therapies of lomitapide (an oral inhibitor of microsomal triglyceride transfer protein), and ANGPTL3-directed therapy (which
Dyslipidaemia
modulates lipid-lipoprotein metabolism and has pleiotropic functions). Finally, lipoprotein apheresis is recommended in children and
adults with HoFH adjunctive to other lipid-lowering therapies, especially in countries without access to newer therapies.

From a global perspective, the authors comment that there is
disparity between high-income and low-income countries in the
identification and management of HoFH. Limited or no access to
new highly effective LDL-lowering therapies and genetic testing
to facilitate identification are important differences, leading
to earlier CV events in patients with HoFH in lower income
countries (mean age 24.5 vs. 37 years).

This updated EAS consensus statement provides pragmatic
guidance fundamental to driving better care and improved CV
health and quality of life for patients with HoFH worldwide.

CLICK HERE
FOR THE LINK TO FULL ARTICLE

WATCH
COMMENTARIES ON THE NEW
GUIDELINES BY SOME OF THE KEY
AUTHORS HERE.

TABLE OF CONTENTS